OJJAARA
Glaxosmithkline Llc
Mark For: OJJAARA™ trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 90058874 |
| Mark Literal Elements | OJJAARA |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | TRADEMARK. SERVICE MARK |
| Register | PRINCIPAL |
| Current Location | INTENT TO USE SECTION 2021-08-03 |
| Basis | 1(b) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | Yes |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Connie Ellerbach |
| Attorney Docket Number | 31899-00070 |
Timeline
| 2020-07-17 | Application Filed |
| 2020-07-21 | Location: NEW APPLICATION PROCESSING |
| 2020-07-21 | Status: Live/Pending |
| 2020-07-21 | Transaction Date |
| 2021-06-08 | Published |
| 2021-08-03 | Location: INTENT TO USE SECTION |
| 2023-08-01 | Status: A fourth request for extension of time to file a Statement of Use has been granted. |
Trademark Parties (Applicants & Owners)
| Party: |  GLAXOSMITHKLINE LLC |
| Address | CORPORATION SERVICE COMPANY 251 LITTLE FALLS DRIVE WILMINGTON, DELAWARE UNITED STATES 19808 |
| Legal Entity Type | Limited Liability Company |
| Legal Entity State | DELAWARE |
| Party: | Sierra Oncology, Inc. |
| Address | 885 West Georgia Street, Ste. 2150 Vancouver, B.C. CANADA V6C3E8 |
| Legal Entity Type | Corporation |
| Legal Entity State | DELAWARE |
*multiple parties listed, check assignment documents for ownership information
Documents
 Application | 2020-07-17 | |
| Drawing | 2020-07-17 | |
| Offc Action Outgoing | 2020-10-30 | |
| XSearch Search Summary | 2020-10-30 | |
| Change Address or Representation Form | 2021-04-27 | |
| Response to Office Action | 2021-04-29 | |
| Amendment and Mail Process Complete | 2021-04-30 | |
| TRAM Snapshot of App at Pub for Oppostn | 2021-05-06 | |
| Notice of Publication | 2021-05-19 | |
| Notification Of Notice of Publication | 2021-05-19 | |
| OG Publication Confirmation | 2021-06-08 | |
| Notice of Allowance | 2021-08-03 | |
| Extension of Time to File SOU | 2022-02-01 | |
| ITU Extension Approval | 2022-02-03 | |
| ITU Unit Action | 2022-02-03 | |
| Extension of Time to File SOU | 2022-07-29 | |
| ITU Extension Approval | 2022-08-02 | |
| ITU Unit Action | 2022-08-02 | |
| Change Address or Representation Form | 2022-10-12 | |
| Change Address or Representation Form | 2022-10-19 | |
| Extension of Time to File SOU | 2023-01-30 | |
| ITU Extension Approval | 2023-02-01 | |
| ITU Unit Action | 2023-02-01 | |
| Extension of Time to File SOU | 2023-08-01 | |
| ITU Extension Approval | 2023-08-03 | |
| ITU Unit Action | 2023-08-03 |
Attorney of Record
Good, Services, and Codes
IC 005. US 005 006 018 044 046 051 052. G & S: Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; Medical diagnostic reagents, assays, and test kits for testing of body fluids; cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use
IC 042. US 100 101. G & S: Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of blood diseases, bone and bone marrow diseases, and cancers; scientific research and development; scientific laboratory services; medical laboratory services; conducting clinical trials for others; conducting clinical trial for others regarding pharmaceutical preparations and drugs in the field of blood diseases, bone and bone marrow diseases, and cancers; DNA screening and analysis services for scientific research purposes
IC 044. US 100 101. G & S: Medical services; medical testing services; DNA screening and analysis services for medical purposes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| International Codes: | 44 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceuticals preparations and drugs; pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; Medical diagnostic reagents, assays, and test kits; cells, proteins, and molecular compounds for medical purposes; DNA damage response assets for medical use |
| GS0051 | Pharmaceutical preparations and drugs for the treatment of cancer, namely, myelofibrosis (mf); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; biological and chemical preparations for the treatment of cancer; pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders |
Assignments
| Description | Date |
|---|---|
 Trademark Assignment 7960-0428 [3 Pages] | 2023-02-03 |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2023-08-03 | |
| SOU TEAS EXTENSION RECEIVED | 2023-08-01 | |
| SOU EXTENSION 4 GRANTED | 2023-08-01 | 98765 |
| SOU EXTENSION 4 FILED | 2023-08-01 | 98765 |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2023-02-15 | |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2023-02-01 | |
| TEAS EXTENSION RECEIVED | 2023-01-30 | |
| SOU TEAS EXTENSION RECEIVED | 2023-01-30 | |
| SOU EXTENSION 3 GRANTED | 2023-01-30 | 98765 |
| SOU EXTENSION 3 FILED | 2023-01-30 | 98765 |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2022-10-19 | |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2022-10-19 | |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2022-10-19 | 88888 |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2022-10-12 | |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2022-10-12 | |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2022-10-12 | |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2022-08-02 | |
| TEAS EXTENSION RECEIVED | 2022-07-29 | |
| SOU TEAS EXTENSION RECEIVED | 2022-07-29 | |
| SOU EXTENSION 2 GRANTED | 2022-07-29 | 98765 |
| SOU EXTENSION 2 FILED | 2022-07-29 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2022-02-03 | |
| TEAS EXTENSION RECEIVED | 2022-02-01 | |
| SOU TEAS EXTENSION RECEIVED | 2022-02-01 | |
| SOU EXTENSION 1 GRANTED | 2022-02-01 | 98765 |
| SOU EXTENSION 1 FILED | 2022-02-01 | 98765 |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2021-08-03 | |
| PUBLISHED FOR OPPOSITION | 2021-06-08 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2021-06-08 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2021-05-19 | |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2021-05-05 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2021-04-29 | 88889 |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2021-04-29 | |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2021-04-29 | 88889 |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2021-04-27 | |
| TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | 2021-04-27 | |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2021-04-27 | |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2021-04-27 | |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2020-10-30 | 6325 |
| NON-FINAL ACTION WRITTEN | 2020-10-30 | 83185 |
| NON-FINAL ACTION E-MAILED | 2020-10-30 | 6325 |
| ASSIGNED TO EXAMINER | 2020-10-30 | 83185 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | 2020-08-14 | |
| NEW APPLICATION ENTERED IN TRAM | 2020-07-21 | |
| NEW APPLICATION ENTERED | 2020-07-21 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 